The last year closed with negative news for tumor immunology. Stimuvax®, an investigational therapeutic anticancer vaccine that Merck licensed from the US biotech firm Oncothyreon, failed to increa...
No takes yet. Share an insight, caveat, or question.
Kroemer et al. (2013) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: